公告日期：2026-04-22

康泰生物:2025年环境、社会和公司治理(ESG)报告(英文)
Founded in 1992, Shenzhen Kangtai Biological Products Co., Ltd. (Stock Code: 300601) is dedicated to the research and development, production and sales of human vaccines. It has
now developed into an innovative biopharmaceutical enterprise with strong R&D capabilities, a rich product portfolio, a leading industrial scale and remarkable international development in China.
The Company has established 5 major R&D and industrial bases in Shenzhen and Beijing, and built diversified R&D platforms covering live attenuated viral vaccines, inactivated viral
vaccines, genetic engineering protein vaccines, bacterial polysaccharide vaccines, bacterial polysaccharide conjugate vaccines, combined vaccines, viral vector vaccines, mRNA
vaccines and new adjuvant technologies, laying a solid foundation for the transformation of cutting-edge vaccine technology achievements into practical applications.
……

[点击查看PDF原文]

提示：本网不保证其真实性和客观性，一切有关该股的有效信息，以交易所的公告为准，敬请投资者注意风险。